ListarGrupo Fisiopatoloxía Endócrina, Nutricional e Médica (FENM) por tema "Somatostatin analogues"
Mostrando ítems 1-3 de 3
-
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
(Taylor&Francis, 2020-05-06)[Abstract] Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish National ... -
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
(BioMed Central, 2015-07-04)[Abstract] Background. Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine ... -
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: the ACROCOMB study
(Elsevier, 2016-11-04)[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated ...